Okay, let's tackle this question. The question is about the co-receptor for the R5 variant of the HIV virus. Hmm, I need to recall what I know about HIV entry mechanisms.

First, HIV uses specific receptors to enter host cells. The primary receptor is CD4, which is on T-helper cells. But there's also a co-receptor involved. I remember that HIV has different strains, like R5 and X4. The R5 variant uses CCR5 as the co-receptor, while X4 uses CXCR4. So the answer should be CCR5. Let me check the options. The correct answer is CCR5.

Wait, why is that the case? The R5 viruses bind to CCR5 because they have a tropism for macrophages and T cells that express this co-receptor. The envelope glycoprotein (gp120) binds to CD4 and then interacts with the co-receptor. For R5, it's CCR5; for X4, it's CXCR4.

Now, the incorrect options might include other receptors like CXCR4, CD8, or maybe CD28. CXCR4 is for X4, so if an option lists CXCR4, that's wrong. CD8 is a receptor on cytotoxic T cells, not involved in HIV entry. CD28 is a co-stimulatory molecule for T cells, not a co-receptor for HIV. Another possible wrong option could be CCR4, which is used by some other viruses, but not R5.

Clinical pearl: Maraviroc is a CCR5 antagonist used to treat R5 HIV strains. So patients with R5 tropism can be treated with this drug. That's a key point for exams.

Let me structure the explanation now. Start with the core concept about HIV entry mechanisms. Then explain why CCR5 is correct. For each wrong option, explain why it's incorrect. Add the clinical pearl about maraviroc. End with the correct answer.

**Core Concept**
The R5 variant of HIV-1 uses **CCR5** as its co-receptor for T-cell entry, alongside CD4. This tropism determines viral replication in macrophages and memory T cells, distinguishing it from X4 variants that use CXCR4. Understanding co-receptor usage is critical for antiretroviral therapy selection.

**Why the Correct Answer is Right**
The R5 HIV variant binds CD4 and the **CCR5 chemokine receptor** to enter host cells. This interaction is mediated by the viral envelope glycoprotein gp120, which adopts a conformation to accommodate CCR5. CCR5 is highly expressed on macrophages and memory T cells, the primary targets of R5-tropic viruses during early infection.

**Why Each Wrong Option is Incorrect**
**Option A:** *CXCR4* is the co-receptor for X4-tropic HIV strains, which emerge in late-stage disease and use a different viral envelope conformation.
**Option B:** *CD8* is a receptor on cytotoxic T cells and has no role in HIV entry.
**Option C:** *CD28* is a T-cell co-stimulatory molecule involved in immune activation, not HIV-1 entry.

**Clinical Pearl / High-Yield Fact**

✓ Correct Answer: B. CCR 5